Press Releases

March 21, 2022

Chimeron Bio Enters Into an Agreement with the NIAID, a Federal Agency, for Pre-clinical Assessment of its Self-Amplifying COVID-19 Vaccine

Philadelphia, PA – Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESARTM RNA delivery platform, today announced it has signed a Non-Clinical Evaluation Agreement (NCEA) with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to evaluate the potential of its vaccine for COVID-19. The Company’s lead candidate, CB-106, delivers the Spike gene as a self-amplifying mRNA.  Preliminary data on this vaccine obtained in collaboration with George Mason University, demonstrated positive results in pre-clinical models with nanogram quantities of RNA, a significant dose advantage over other RNA based technologies. In addition to CB-106, other ChaESAR candidates under testing by the Company include particles co-delivering multi-variant antigens for viral and non-viral vaccines for broad spectrum protection.    

Under the current agreement, Chimeron Bio will utilize the pre-clinical services program offered by the NIAID.  Chimeron Bio will provide the vaccine candidate to test in the hamster model of COVID-19 which has previously been used for the assessment of other COVID-19 vaccines.  “A successful outcome from this study will further validate ChaESAR™ technology in pre-clinical models and boost the design of a next generation single shot RNA vaccine that is durable, low dose, low cost, scalable and can render broad-spectrum protection against multiple variants or infectious agents” said Thimmaiah Chendrimada, Co-founder and CSO of Chimeron Bio.   

“We are grateful to receive NIAID’s support and work with NIAID funded world-class institutions. The COVID-19 program is Chimeron’s first foray into infectious diseases, and we expect the data from the current study to offer critical validation to advance CB-106 into non-human primates and demonstrate the applicability of ChaESAR™ technology for vaccines at large ” said Jolly Mazumdar, Co-founder and CEO of Chimeron Bio.  

About Chimeron Bio 

Chimeron Bio is a biotechnology company focused on the development of self-amplifying RNA (saRNA) therapeutics and vaccines across therapeutic areas. The company is using its proprietary ChaESARTM platform to develop a pipeline of products in oncology, rare genetic disorders, and infectious diseases.  For more information, visit

Media Inquiries

Interested in learning more about Chimeron Bio’s novel technology and the work we are doing to develop first-in-class self-amplifying RNA therapeutics?

Reach out to us at today.

Follow Us